ALS Treatment Overview

ALS Treatment Overview

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">ALS Treatment Overview</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>ALS Treatment Overview</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Therapeutic</td>
</tr>
</table>

[Amyotrophic lateral sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis), also known as Lou Gehrig's disease, is a progressive neurodegenerative disorder characterized by the selective loss of upper and lower motor neurons in the brain and spinal cord[@brown2017]. This leads to progressive muscle weakness, paralysis, and ultimately respiratory failure, typically within 2-5 years of symptom onset[@chio2013]. Approximately 10% of cases are familial, with [C9orf72](/entities/c9orf72), SOD1, FUS, and TARDBP being the most common genetic causes[@renton2014]. The remaining 90% are sporadic, with complex multifactorial etiology involving glutamate excitotoxicity, oxidative stress, mitochondrial dysfunction, neuroinflammation, and impaired RNA metabolism[@hardiman2017].

FDA-Approved Disease-Modifying Therapies

Riluzole (Rilutek)

Riluzole, approved in 1995, remains the cornerstone of disease-modifying therapy for ALS[@lacomblez1996]. The drug acts primarily by inhibiting glutamate release, reducing excitatory neurotransmission, and modulating sodium channels.

Clinical benefits: 2-3 month survival benefit, with more pronounced effects in patients with bulbar-onset disease[@miller2012]

ALS Treatment Overview

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">ALS Treatment Overview</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>ALS Treatment Overview</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Therapeutic</td>
</tr>
</table>

[Amyotrophic lateral sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis), also known as Lou Gehrig's disease, is a progressive neurodegenerative disorder characterized by the selective loss of upper and lower motor neurons in the brain and spinal cord[@brown2017]. This leads to progressive muscle weakness, paralysis, and ultimately respiratory failure, typically within 2-5 years of symptom onset[@chio2013]. Approximately 10% of cases are familial, with [C9orf72](/entities/c9orf72), SOD1, FUS, and TARDBP being the most common genetic causes[@renton2014]. The remaining 90% are sporadic, with complex multifactorial etiology involving glutamate excitotoxicity, oxidative stress, mitochondrial dysfunction, neuroinflammation, and impaired RNA metabolism[@hardiman2017].

FDA-Approved Disease-Modifying Therapies

Riluzole (Rilutek)

Riluzole, approved in 1995, remains the cornerstone of disease-modifying therapy for ALS[@lacomblez1996]. The drug acts primarily by inhibiting glutamate release, reducing excitatory neurotransmission, and modulating sodium channels.

Clinical benefits: 2-3 month survival benefit, with more pronounced effects in patients with bulbar-onset disease[@miller2012]

Dosing: 50 mg twice daily, with monitoring of liver function

Side effects: Dizziness, fatigue, nausea

Edaravone (Radicava)

Edaravone, approved in 2017, is a free radical scavenger that reduces oxidative stress, a key pathological mechanism in ALS.

Clinical benefits: Reduced functional decline measured by ALSFRS-R score[@abe2017]

Administration: IV infusion for 14 days followed by 14-day drug-free periods

Side effects: Bruising, gait disturbance, headache

AMX0035 (Relyvrio)

AMX0035 (sodium phenylbutyrate/taurursodiol), approved in 2022, targets mitochondrial dysfunction and endoplasmic reticulum stress.

Clinical benefits: Median 9.7 months survival benefit in CENTAUR trial[@paganoni2020]

Administration: Oral powder mixed with water

Side effects: Diarrhea, abdominal pain, nausea

Tofersen (Qalsody)

Tofersen, approved in 2023, is an antisense oligonucleotide (ASO) therapy specifically targeting SOD1 gene mutations, which account for approximately 2% of all ALS cases[@millert2020].

Mechanism: Reduces SOD1 protein production through RNA splicing modification

Clinical outcomes: Significant reduction in SOD1 protein and neurofilament light chain (NfL) levels[@valeras2023]

Administration: Intrathecal injection every 28 days

Requirement: Confirmed SOD1 mutation for treatment[fda2023]

Symptomatic Management

Muscle Cramps and Spasticity

• Mexiletine: Sodium channel blocker, reduces cramp frequency
• Baclofen: GABA-B agonist, 5-40 mg TID
• Tizanidine: Alpha-2 adrenergic agonist

Dysphagia and Nutrition

• Early nutritional assessment is critical
• PEG tube placement when weight loss exceeds 10%
• High-calorie supplements for metabolic demands

Respiratory Management

• Non-invasive ventilation (NIV): Improves survival and quality of life[@bourke2006]
• Cough assist devices: Clear secretions when peak cough flow <270 L/min
• Invasive ventilation: Option for maximal life extension

Sialorrhea Management

• Botulinum toxin injections into salivary glands
• Anticholinergic medications (glycopyrrolate, scopolamine)

Pseudobulbar Affect

• Dextromethorphan/quinidine (Nuedexta): FDA-approved for PBA in ALS

Multidisciplinary Care

Multidisciplinary ALS clinics improve survival and quality of life compared to standard care[@traynor2003]. Core team includes:

• Neurology for diagnosis and disease-modifying therapy management
• Pulmonology for respiratory assessment
• Gastroenterology for nutrition and PEG placement
• Physical and occupational therapy
• Speech therapy for communication and dysphagia
• Social work and palliative care

Emerging Therapies

Gene Therapy Approaches

C9orf72-Targeting Therapies: ASOs and small molecules targeting the C9orf72 hexanucleotide repeat expansion, the most common genetic cause of ALS, are in various trial stages[@liu2024].

FUS-Targeting Therapies: ASO therapies targeting FUS mutations are in development.

Stem Cell Therapies

Neural stem cell transplantation trials have evaluated delivery to the spinal cord, showing preliminary safety and potential biological effects[@glass2022].

Neuroprotective Strategies

• Ibudilast: PDE4/MIF inhibitor in Phase II trials
• Masitinib: Tyrosine kinase inhibitor in phase III trials

Treatment Algorithm

For comprehensive treatment protocols and detailed therapeutic approaches, see [Amyotrophic Lateral Sclerosis Treatment](/therapeutics/amyotrophic-lateral-sclerosis-treatment).

Conclusion

ALS treatment has advanced significantly with four FDA-approved disease-modifying therapies (riluzole, edaravone, AMX0035, tofersen). Comprehensive management through multidisciplinary care remains essential for optimizing outcomes. Emerging gene therapies and stem cell approaches offer future promise for this devastating disease.

References

See Also

• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [C9orf72 Gene](/entities/c9orf72)
• [SOD1 Gene](/entities/sod1)
• [Neurofilament Light Chain](/biomarkers/neurofilament-light-chain-nfl)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Cryptic Exon Silencing Restoration](/hypothesis/h-4fabd9ce) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: TARDBP
• [Cross-Seeding Prevention Strategy](/hypothesis/h-eea667a9) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: TARDBP
• [Glycine-Rich Domain Competitive Inhibition](/hypothesis/h-7e846ceb) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: TARDBP
• [RNA-Binding Competition Therapy for TDP-43 Cross-Seeding](/hypothesis/h-7693c291) — <span style="color:#ffd54f;font-weight:600">0.49</span> · Target: TARDBP

• [Microglial subtypes in neurodegeneration — friend vs foe](/analysis/SDA-2026-04-02-gap-microglial-subtypes-20260402004119) &#x1f504;
• [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) &#x1f504;
• [RNA binding protein dysregulation across ALS FTD and AD](/analysis/SDA-2026-04-01-gap-v2-68d9c9c1) &#x1f504;
• [CRISPR-based therapeutic approaches for neurodegenerative diseases](/analysis/SDA-2026-04-02-gap-crispr-neurodegeneration-20260402) &#x1f504;
• [RNA binding protein dysregulation across ALS FTD and AD](/analysis/SDA-2026-04-01-gap-v2-68d9c9c1) &#x1f504;